tbuckley/cabot-search huggingface dataset:
P2-019: Reduced expression of DNA mismatch repair gene hMLH protein involves early stage of carcinogenesis of chromate lung cancer
Authors: Taeko Nagao, Kazuya Kondo, Yuji Takahashi, Yukiko Hirose, Hiroaki Toba, Takanori Miyoshi, Shoji Sakiyama, Akira Tangoku
Journal: Journal of Thoracic Oncology (2007)
IgE immunotherapy of solid tumours: a novel model targeting folate receptor alpha (FR alpha)-positive carcinomas with MOv18 IgE
Authors: D. Josephs, S. Rudman, P. Karagiannis, A. E. Gilbert, H. J. Gould, F. O. Nestle, J. Spicer, Sophia Karagiannis
Journal: British Journal of Dermatology (2011)
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Authors: Amanda J. Walker, Suparna Wedam, Laleh Amiri-Kordestani, Erik Bloomquist, Shengui Tang, Rajeshwari Sridhara, Wei Chen, Todd R. Palmby, Jeanne Fourie Zirkelbach, Wentao Fu, Qi Liu, Amy Tilley, Geoffrey Kim, Paul G. Kluetz, Amy E. McKee, Richard Pazdur
Journal: Clinical Cancer Research (2016)

On February 19, 2016, the FDA approved palbociclib (Ibrance, Pfizer) for use in combination with fulvestrant (Faslodex, AstraZeneca) for the treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer (MBC) with disease progression following endocrine therapy. The approval was based on the results of a randomized, double-blind, placebo-controlled trial conducted in 521 pre- and postmenopausal women with HR-positive, HER2-negative advanced or MBC. Patients were randomized (2:1) to receive palbociclib plus fulvestrant (n = 347) or placebo plus fulvestrant (n = 174). The primary endpoint was investigator-assessed progression-free survival (PFS). A statistically significant and clinically meaningful improvement in PFS (9.5 months vs. 4.6 months) was observed in patients receiving palbociclib plus fulvestrant [HR 0.46; 95% confidence interval (CI), 0.36-0.59; P < 0.0001]. Safety data confirmed the known adverse reaction profile of palbociclib. The most common adverse reactions (>20%) in patients treated with palbociclib were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, headache, diarrhea, and thrombocytopenia. This approval was granted in the context of a prior accelerated approval for palbociclib in combination with letrozole in patients with HR-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy. Clin Cancer Res; 22(20); 4968-72. ©2016 AACR.
Focus on Surgical Outcomes That Matter to Older Patients
Authors: Anne M. Suskind, Emily Finlayson
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Staging Bone Marrow Biopsy Does Not Alter Management in Patients with Hodgkin Lymphoma and May Not be Necessary:a 10yr Single Institutional Retrospective Review of Patients with Hodgkin Lymphoma with Bone Marrow Involvement 2004-2013
Authors: Moyosore M. Suleiman, Ankit Mangla, Hussein Hamad, Romy Thekekkara, Kalid Adab, Rosalind Catchatourian
Journal: Blood (2014)
Role of <sup>18</sup>F-FDG PET/CT in predicting the outcomes of spinal metastasis treated with Cyberknife radiosurgery in patients with sarcoma.
Authors: Chang-Bae Kong, Byung Hyun Byun, Sang Moo Lim
Journal: Journal of Clinical Oncology (2015)

e21503 Background: The aim of this study was to evaluate the usefulness of 18F-FDG PET/CT (PET) in predicting infield tumor recurrence after Cyberknife radiosurgery (CKS) in patients with metastatic sarcoma to the spine. Methods: From Jan 2005 to Dec 2012, 34 patients were treated with CKS for spinal metastasis from bone- or soft tissue sarcoma. Among these, 9 patients with baseline PET within 4 months before CKS and sequential PET within 6 months after CKS were retrospectively analyzed. The median delivered radiation dose of CKS was 36 Gy (range, 23–45) in 1 to 4 fractions (median, 3 fractions). For visual analysis of PET, spinal metastasis demonstrating 18F-FDG uptake greater than adjacent normal spine was considered as FDG-avid spinal metastasis. For semi-quantitative analysis, the maximum standardized uptake value (SUVmax) and metabolic tumor volume at the cut-off SUV of 2.5 (MTV) of metastatic tumor and their % changes were calculated on each PET data set. We followed-up for more than 18 months for infield recurrence-free patients. ROC curve analyses and the Kaplan-Meier methods were used to analyze whether PET parameters could predict infield recurrence-free survival. Results: FDG-avid spinal metastases were delineated in 9 patients (100%) at baseline PET and 8 patients (89%) at sequential PET. Up to the time of analysis, 5 patients (56%) had experienced infield recurrence. Of the PET parameters, only MTV at baseline PET (MTV1) predicted infield recurrence by ROC curve analysis (area under the curve = 0.900, P < 0.001). Patients with MTV1 > 6 mL had worse 1-y (25% vs. 80%) and 3-y (0% vs. 80%) infield recurrence-free survival than patients with MTV1 < 6 mL (P = 0.059, log-rank test). Conclusions: Baseline PET may be useful to predict the infield tumor recurrence following CKS for metastatic sarcoma to the spine.
Injectable alginate hydrogel for enhanced spatiotemporal control of lentivector delivery in murine skeletal muscle
Authors: Roberta S. Stilhano, Justin L. Madrigal, Kevin Wong, Priscilla A. Williams, Priscila K.M. Martin, Fabio S.M. Yamaguchi, Vivian Y. Samoto, Sang W. Han, Eduardo A. Silva
Journal: Journal of Controlled Release (2016)
Estimated Cost of Injectable Medication Waste Attributable to Syringe Dead Space
Authors: Christine U. Oramasionwu, Ashley L. Cole, Matthew S. Dixon, Susan J. Blalock, Gary A. Zarkin, Laura J. Dunlap, William A. Zule
Journal: JAMA Internal Medicine (2016)

the simplified regimen was that many patients were able to adjust the dose of glargine when glucose levels changed with other health issues during the no-contact period.Another important finding of the study is that the level of HbA 1c did not correlate with duration of hypoglycemia before or after simplification of the regimen, suggesting that HbA 1c level is a poor predictor of the risk of hypoglycemia.Our previous study has shown that the HbA 1c levels may not correlate with estimated average glucose in older populations. 7The combination of these findings suggests that liberating the HbA 1c goals in frail older patients is not adequate to protect against the risk of hypoglycemia.The type of glucose-lowering agents and the strategy for their use are important to lower the risk of hypoglycemia.Conclusions | Our study shows that (1) simplification of insulin regimens in older adults can decrease hypoglycemia risk and disease-related distress without compromising glycemic control; and (2) HbA 1c levels may not predict the risk of hypoglycemia in the older population and should not be used as the sole parameter for goal setting.
Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease
Authors: Samantha L. Passey, Michelle J. Hansen, Steven Bozinovski, Christine F. McDonald, Anne E. Holland, Ross Vlahos
Journal: Pharmacology & Therapeutics (2016)

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that constitutes a major global health burden. A significant proportion of patients experience skeletal muscle wasting and loss of strength as a comorbidity of their COPD, a condition that severely impacts on their quality of life and survival. At present, the lung pathology is considered to be largely irreversible; however, the inherent adaptability of muscle tissue offers therapeutic opportunities to tackle muscle wasting and potentially reverse or delay the progression of this aspect of the disease, to improve patients' quality of life. Muscle wasting in COPD is complex, with contributions from a number of factors including inflammatory cytokines, oxidative stress, growth and anabolic hormones, nutritional status, and physical activity. In this review, we discuss current and emerging therapeutic approaches to treat muscle wasting in COPD, including a number of pharmacological therapies that are in development for muscle atrophy in other pathological states that could be of relevance for treating muscle wasting in COPD patients.
The Nineteen Forty Mental Measurements Yearbook
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopic suturing for the prevention of stent migration in benign upper gastrointestinal conditions: a comparative multicenter study
Authors: Saowanee Ngamruengphong, Reem Sharaiha, Amrita Sethi, Ali Siddiqui, Christopher DiMaio, Susana Gonzalez, Jennifer Im, Jason Rogart, Sophia Jagroop, Jessica Widmer, Raza Hasan, Sobia Laique, Tamas Gonda, John Poneros, Amit Desai, Amy Tyberg, Vivek Kumbhari, Mohamad El Zein, Ahmed Abdelgelil, Sepideh Besharati, Ruben Hernaez, Patrick Okolo, Vikesh Singh, Anthony Kalloo, Michel Kahaleh, Mouen Khashab
Journal: Endoscopy (2016)

<b>Background and study aims: </b>Fully covered self-expandable metal stents (FCSEMSs) have increasingly been used in benign upper gastrointestinal (UGI) conditions; however, stent migration remains a major limitation. Endoscopic suture fixation (ESF) may prevent stent migration. The aims of this study were to compare the frequency of stent migration in patients who received endoscopic suturing for stent fixation (ESF group) compared with those who did not (NSF group) and to assess the impact of ESF on clinical outcome. <b>Patients and methods:</b> This was a retrospective study of patients who underwent FCSEMS placement for benign UGI diseases. Patients were divided into either the NSF or ESF group. Outcome variables, including stent migration, clinical success (resolution of underlying pathology), and adverse events, were compared. <b>Results: </b>A total of 125 patients (44 in ESF group, 81 in NSF group; 56 benign strictures, 69 leaks/fistulas/perforations) underwent 224 stenting procedures. Stent migration was significantly more common in the NSF group (33 % vs. 16 %; <i>P</i> = 0.03). Time to stent migration was longer in the ESF group (<i>P</i> = 0.02). ESF appeared to protect against stent migration in patients with a history of stent migration (adjusted odds ratio [OR] 0.09; <i>P</i> = 0.002). ESF was also significantly associated with a higher rate of clinical success (60 % vs. 38 %; <i>P</i> = 0.03). Rates of adverse events were similar between the two groups. <b>Conclusions: </b>Endoscopic suturing for stent fixation is safe and associated with a decreased migration rate, particularly in patients with a prior history of stent migration. It may also improve clinical response, likely because of the reduction in stent migration.
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
Authors: Janet Retseck, Robert VanderWeele, Hui-Min Lin, Yan Lin, Lisa H. Butterfield, Ahmad A. Tarhini
Journal: Journal for ImmunoTherapy of Cancer (2016)

<h3>Background</h3> We have previously investigated neoadjuvant ipilimumab (ipi) for patients with locally/regionally advanced melanoma. That initial assessment of peripheral blood mononuclear cells (PBMC) showed a significant increase in shared tumor associated antigen specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell activation. We also observed a transient increase in circulating T regulatory cells (Treg) with a parallel increase in total CD4<sup>+</sup> T cells, as well as a significant decrease in circulating myeloid derived suppressor cells (MDSC). The increase in circulating Treg frequency, as assessed at 6&nbsp;weeks after initiation of ipilimumab, was significantly associated with improved progression free survival (PFS, <i>p</i> = 0.034; HR = 0.57) and returned to baseline levels by 12&nbsp;weeks. To shed light on the unexpected positive correlation between increased Treg and PFS, we here investigated the suppressive activity of circulating Treg at baseline and 6&nbsp;weeks. <h3>Methods</h3> Patients were treated with ipi (10&nbsp;mg/kg intravenously every 3&nbsp;weeks for 2 doses) bracketing definitive surgery. Treg (CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>dim/-</sup>) were isolated from pre-ipi (baseline) and post-ipi (6&nbsp;weeks) PBMC samples. Treg were co-cultured with autologous responder CD4<sup>+</sup> T cells that were stimulated with OKT3/IL-2/CD28 and CFSE-labeled T cells. 1:1, 1:2, and 1:5 ratios were tested. Flow cytometery was used to evaluate the degree of Treg proliferation suppression. <h3>Results</h3> Thirty-five patients were enrolled in the study; 18 patients had adequate PBMC samples with sufficient Treg isolated for Treg functional analysis. At 6&nbsp;weeks following ipi, a decrease in percent of maximal inhibition of Th by Treg compared to baseline was seen for some patients. Scatter plot analysis showed no association between Treg frequency and function at any ratio or between circulating Treg frequency and function at baseline and at 6&nbsp;weeks post-ipi. An increase in Treg suppressive function was significantly associated with a decrease in PFS (<i>p</i> = 0.02). <h3>Conclusions</h3> We find that Treg frequency measures do not correlate with suppressive activity measured ex vivo. Treg suppressive activity increases correlate with poorer patient outcomes.
Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions
Authors: Jian Gu, Xuhao Ni, Xiongxiong Pan, Hao Lu, Yunjie Lu, Jie Zhao, Song Guo Zheng, Keli L Hippen, Xuehao Wang, Ling Lu
Journal: Cellular and Molecular Immunology (2016)

Autoimmune diseases are characterized by an imbalance between regulatory T cells and effector T-cell subsets, such as Th1 and Th17 cells. Studies have confirmed that natural CD4+Foxp3+ Tregs were unstable and dysfunctional in the presence of pro-inflammatory cytokines. In the current study, human CD39hi Tregs and CD39low Tregs were sorted from Tregs in vitro after 7 days of expansion. The functions of both Treg subsets were investigated under inflammatory conditions in vitro and in vivo. In the presence of IL-1β and IL-6, cultured CD4+CD39hi Tregs maintained stable forkhead box protein 3 expression, whereas CD4+CD39low Tregs lost Foxp3 expression and trans-differentiated into Th1 or Th17 cells. Decreased IL-1βR and IL-6R expression on the CD39hi Tregs was the primary mechanism responsible for Treg stability. In addition, reduced activation of downstream molecules, such as STAT1 and STAT3, through the modulation of CpG demethylation played an important role. Finally, human CD4+CD39hi Tregs but not CD4+CD39low Tregs protected against xenograft versus host disease in model mice. These results strongly implied the physiological importance of CD39 expression and suggested that manipulation of CD39hi Tregs might represent a novel strategy for the treatment of autoimmune diseases.
Case 42-1968
Authors: Marian W. Ropes, Benjamin Castleman
Journal: New England Journal of Medicine (1968)

Presentation of CaseAn eighty-year-old physician was admitted to the hospital because of urinary frequency and urgency and dysuria.For thirty years he had had progressive rheumatoid arthritis associated with keratitis sicca. X-ray films of the knees taken twenty-three years before entry revealed narrowing of the menisci bilaterally. Twenty years before entry he had several episodes of pain in the chest associated with fever, and x-ray films of the chest revealed multiple areas of increased density in the lower lung fields, with several linear shadows extending to the pleural surface of the right middle lobe. The diagnosis of pulmonary infarction . . .
Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families
Authors: H Hermesh, D Aizenberg, M Lapidot, H Munitz
Journal: American Journal of Psychiatry (1988)

The occurrence of malignant hyperthermia in 20 patients who had had neuroleptic malignant syndrome and in their 108 first-degree relatives was retrospectively studied. The patients had experienced a total of 20 courses of ECT and 12 surgical operations in which drugs that can cause malignant hyperthermia were used, but no cases of malignant hyperthermia had occurred, and no cases had occurred in the 37 relatives who had undergone surgery or ECT. The authors conclude that patients who have had malignant neuroleptic syndrome are not at considerably greater risk than others for developing malignant hyperthermia during surgery or ECT; the clinical data suggest that the two disorders are not related.
Global distribution and environmental suitability for chikungunya virus, 1952 to 2015
Authors: Elaine O Nsoesie, Moritz UG Kraemer, Nick Golding, David M Pigott, Oliver J Brady, Catherine L Moyes, Michael A Johansson, Peter W Gething, Raman Velayudhan, Kamran Khan, Simon I Hay, John S Brownstein
Journal: Eurosurveillance (2016)

Chikungunya fever is an acute febrile illness caused by the chikungunya virus (CHIKV), which is transmitted to humans by Aedes mosquitoes. Although chikungunya fever is rarely fatal, patients can experience debilitating symptoms that last from months to years. Here we comprehensively assess the global distribution of chikungunya and produce high-resolution maps, using an established modelling framework that combines a comprehensive occurrence database with bespoke environmental correlates, including up-to-date Aedes distribution maps. This enables estimation of the current total population-at-risk of CHIKV transmission and identification of areas where the virus may spread to in the future. We identified 94 countries with good evidence for current CHIKV presence and a set of countries in the New and Old World with potential for future CHIKV establishment, demonstrated by high environmental suitability for transmission and in some cases previous sporadic reports. Aedes aegypti presence was identified as one of the major contributing factors to CHIKV transmission but significant geographical heterogeneity exists. We estimated 1.3 billion people are living in areas at-risk of CHIKV transmission. These maps provide a baseline for identifying areas where prevention and control efforts should be prioritised and can be used to guide estimation of the global burden of CHIKV.
The prevalence of schizophrenia: a reassessment using modern diagnostic criteria
Authors: M A Taylor, R Abrams
Journal: American Journal of Psychiatry (1978)

Using strict research diagnosis criteria, the authors found a hospital admission prevalence of schizophrenia of about 6%. Other recent studies yielded similar figures, with correspondingly low figures for the morbid risk of schizophrenia in the general population and in the relatives of schizophrenic probands. In view of the data supporting the validity of this "narrow" concept of schizophrenia, the authors suggest that the true prevalence of schizophrenia is much lower than generally accepted.
Annual Meeting of American Association for Cancer Research
Authors: F Lavelle, J P Armand
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Annual Meeting of American Association for Cancer Research Get access JNCI: Journal of the National Cancer Institute, Volume 50, Issue 2, February 1973, Page 580, https://doi.org/10.1093/jnci/50.2.580 Published: 01 February 1973
Mad Dog
Authors: M. Therese Southgate
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Changing Dietary Habits and Improving the Healthiness of Diets in the United States
Authors: Margo A. Denke
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal